MeiraGTx Holdings (MGTX) Free Cash Flow (2017 - 2025)
MeiraGTx Holdings' (MGTX) quarterly Free Cash Flow came in at $46.4 million in Q4 2025, up 289.27% YoY from $11.9 million in Q4 2024, and up 461.47% on a QoQ basis from -$12.8 million in Q3 2025.
Analysis
MeiraGTx Holdings (MGTX) Free Cash Flow (2017 - 2025) Analysis & Trends
MeiraGTx Holdings (MGTX) has 9 years of Free Cash Flow data on file, last reported at $46.4 million in Q4 2025.
- Quarterly Free Cash Flow rose 289.27% year-over-year to $46.4 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$50.2 million (up 54.15% YoY) and the FY2025 annual result came in at -$50.2 million, up 54.15% from the prior year.
- Free Cash Flow grew to $46.4 million in Q4 2025, from -$12.8 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $46.4 million in Q4 2025 to a low of -$61.1 million in Q4 2022.
- A 5-year average of -$22.1 million and a median of -$25.1 million in 2024 frame the typical range for Free Cash Flow.
- Annual changes were most pronounced in 2022 — Free Cash Flow tumbled 1003.03% — and 2025, when it surged 289.27%.
- Tracing MGTX's Free Cash Flow over 5 years: stood at -$5.5 million in 2021, then plunged by 1003.03% to -$61.1 million in 2022, then jumped by 73.26% to -$16.3 million in 2023, then sank by 49.89% to -$24.5 million in 2024, then surged by 289.27% to $46.4 million in 2025.
- The last three Free Cash Flow figures came in at $46.4 million (Q4 2025), -$12.8 million (Q3 2025), and -$45.2 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.01 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 572.80 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -563.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -389.61 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 437.80 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 292.04 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 477.44 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -95.09 Mn |
| 10 | MeiraGTx Holdings | 1.27 Bn | 1.13 Bn | 315.67 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 46.33 Mn |
| Sep 30, 2025 | -12.84 Mn |
| Jun 30, 2025 | -45.18 Mn |
| Mar 31, 2025 | -38.54 Mn |
| Dec 31, 2024 | -24.49 Mn |
| Sep 30, 2024 | -25.75 Mn |
| Jun 30, 2024 | -20.79 Mn |
| Mar 31, 2024 | -38.42 Mn |
| Dec 31, 2023 | -17.58 Mn |
| Sep 30, 2023 | -27.98 Mn |
| Jun 30, 2023 | -33.99 Mn |
| Mar 31, 2023 | -46.00 Mn |
| Dec 31, 2022 | -24.76 Mn |
| Sep 30, 2022 | -30.74 Mn |
| Jun 30, 2022 | -41.81 Mn |
| Mar 31, 2022 | -20.76 Mn |
| Dec 31, 2021 | -5.54 Mn |
| Sep 30, 2021 | -29.09 Mn |
| Jun 30, 2021 | -26.84 Mn |
| Mar 31, 2021 | 4.58 Mn |